| Budget Amount *help |
¥13,800,000 (Direct Cost: ¥13,800,000)
Fiscal Year 2002: ¥1,800,000 (Direct Cost: ¥1,800,000)
Fiscal Year 2001: ¥3,100,000 (Direct Cost: ¥3,100,000)
Fiscal Year 2000: ¥3,900,000 (Direct Cost: ¥3,900,000)
Fiscal Year 1999: ¥5,000,000 (Direct Cost: ¥5,000,000)
|
|---|
| Research Abstract |
Stability of the immunoconjugate had been examined both in the room temperature and freezer. Drug activity and antibody activity were perfectly reserved at least 12 months in the freezer. The safety of the chimeric antibody part of the immunoconjugate chA7-NCS could not be confirmed yet. The phase I clinical study to evaluate the maximum tolerant dose of the immunoconjugate , human immune reaction, and biodistribution of the conjugate could not be finished. Next step of this project should be the phase I clinical study of immunoconjugate.
|
